MarketBeat on MSN16h
Biotechs on the Brink: 2 Stocks With Huge PotentialInvestors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...
GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...
A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.
The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...
GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback